{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"62","upperLimit":"90","value":"76"}]}],"title":"Non-Smokers"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"79","upperLimit":"99","value":"89"}]}],"title":"Smokers that quit while on study"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25","upperLimit":"75","value":"50"}]}],"title":"Smokers"}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Percent of patients that were progression free by smoking status","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically indicated.\n\nPatients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months after completion of study treatment, and at disease progression. Patients complete Sexual Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3 months after completion of study treatment, and at disease progression.","id":"OG000","title":"Treatment (Cisplatin, Triapine, Radiation Therapy)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 18 months from study entry","title":"Progression Free Survival by Smoking Status","type":"POST_HOC","unitOfMeasure":"percentage of paticipants"}